|1.||Krege, John H: 21 articles (01/2015 - 03/2005)|
|2.||Bilezikian, John P: 18 articles (01/2014 - 03/2004)|
|3.||Marin, Fernando: 16 articles (02/2014 - 05/2006)|
|4.||Miller, Paul D: 15 articles (06/2015 - 10/2002)|
|5.||Chen, Peiqi: 14 articles (05/2012 - 06/2005)|
|6.||Cosman, Felicia: 11 articles (07/2015 - 03/2004)|
|7.||Nakamura, Toshitaka: 11 articles (07/2014 - 01/2008)|
|8.||Sugimoto, Toshitsugu: 10 articles (09/2015 - 09/2010)|
|9.||Fahrleitner-Pammer, Astrid: 9 articles (02/2014 - 02/2008)|
|10.||Boonen, Steven: 9 articles (08/2011 - 05/2006)|
09/01/2012 - "As the first FDA-approved anabolic agent for osteoporosis, teriparatide has proven effective for people at highest risk of fracture, despite limitations of expense, route of delivery, and length of treatment. "
09/01/2010 - "This multicenter study assessed the safety and efficacy of teriparatide 20 microg/day in Japanese men and women with osteoporosis at high risk of fracture during a 12-month, randomized, double-blind, placebo-controlled treatment period followed by second and third treatment periods (to 18 and 24 months, respectively,) in which all subjects received open-label teriparatide. "
11/01/2003 - "These data show that teriparatide treatment of postmenopausal women with osteoporosis significantly increased cancellous bone volume and connectivity, improved trabecular morphology with a shift toward a more plate-like structure, and increased cortical bone thickness. "
07/01/2015 - "Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature."
06/01/2008 - "These results show that teriparatide is an effective and safe drug in increasing the BMD and therefore, teriparatide provides yet another new therapeutic option for reducing the risk management of osteoporosis in postmenopausal women (clinicaltrials.gov number, NCT00500409)."
04/01/2012 - "Anabolic treatment with teriparatide has proven effective for the therapy of postmenopausal osteoporosis and significantly reduces the risk of non-vertebral fragility fractures. "
01/01/2013 - "EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during subsequent treatment with other medications. "
02/01/2012 - "All trials aimed to evaluate the efficacy of daily subcutaneous teriparatide injection in postmenopausal osteoporosis. "
02/01/2012 - "To determine the efficacy of teriparatide supplementation for improving bone mineral density (BMD) and fracture risk in postmenopausal osteoporosis and if effects vary with factors. "
01/01/2012 - "The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden."
|3.||Back Pain (Backache)
01/01/2006 - "Teriparatide-treated patients had a reduced incidence of back pain versus those receiving a comparator during an observation encompassing clinical trials plus 30 months of posttreatment observation."
05/01/2013 - "A primary objective of this retrospective study was to define the efficacy of teriparatide in terms of bone mineral density (BMD) changes and relief of back pain in clinical practice. "
01/01/2014 - "The European Forsteo Observational Study assessed the clinical fracture incidence, back pain, quality of life (QoL), and treatment persistence amongst post-menopausal women, who were prescribed teriparatide in routine care in eight European countries. "
01/01/2014 - "Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study."
09/01/2012 - "The aims of this study were to evaluate the effectiveness of teriparatide treatment on back pain-related functional limitations and to investigate on patients HRQoL. "
01/01/2014 - "Teriparatide treatment also resulted in a significant reduction in self-reported pain intensity and a significant improvement in physical health as measured by VAS and ODI scores, respectively. "
12/01/2012 - "Pain and tenderness improved remarkably after teriparatide treatment for 1 month, and these symptoms disappeared after teriparatide treatment for 9 months. "
03/01/2010 - "Pain resolved and mobility improved with teriparatide treatment. "
04/01/2015 - "A prospective observational study between April 2006 and February 2014 was done with 77 patients treated with teriparatide in the Pain Unit of Hospital Obispo Polanco of Teruel (Spain). "
04/01/2015 - "The aim of this study was to analyse the effect of teriparatide (TPTD) in osteoporotic patients with vertebral pain. "
09/01/2015 - "Teriparatide therapy was safe, with no adverse events noted, and completely eliminated symptomatic hypocalcemia in all treated patients within 24 hours of initiation. "
11/01/2015 - "hPTH 1-34 must be gradually weaned in hypoparathyroid patients with high doses of oral medications given to avoid hypocalcemia. "
11/01/2015 - "Thus, to avoid hypocalcemia, subjects were slowly weaned from hPTH 1-34 over several weeks. "
11/01/2015 - "Two subjects developed hypocalcemia when hPTH 1-34 was abruptly discontinued. "
08/15/2011 - "Teriparatide therapy was initiated 32±14 days after the development of hypocalcemia. "
|2.||Parathyroid Hormone (Parathormone)
|3.||Alendronate (Alendronate Sodium)
|6.||risedronic acid (risedronate)
|9.||Biological Markers (Surrogate Marker)